Medical Research Council – Page 3 – Communicable Diseases Research

One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study

Observational Study

Published on 2022-03-212022-10-05
Journal: Respiratory Research [Category] 임상,

Qingjin Yiqi granules for post-COVID-19 condition: A randomized clinical trial

Randomized Controlled Trial

Published on 2022-03-012022-10-04
Journal: Journal of evidence-based medicine [Category] 임상,

Establishing CREATE: lessons learned in setting up a training environment for early-career researchers in respiratory medicine

Research

Published on 2022-03-012022-10-28
Journal: BMC Medical Education [Category] Coronavirus, MERS, SARS,

Evaluation of the Post-COVID-19 Functional Status (PCFS) Scale in a cohort of patients recovering from hypoxemic SARS-CoV-2 pneumonia

저산소증 SARS-CoV-2 폐렴에서 회복 중인 환자 코호트에서 코로나19 이후 기능 상태(PCFS) 척도 평가

Article

Published on 2022-03-012022-09-11
Journal: BMJ Open Respiratory Research [Category] SARS, 치료기술,

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

입원한 COVID-19 환자의 표준 치료와 비교한 나밀루맙 또는 인플릭시맙(CATALYST): 무작위, 다기관, 다군, 다단계, 공개 라벨, 적응형, 2상, 개념 증명 시험

Clinical Trial

Published on 2022-03-012022-09-12
Journal: The Lancet. Respiratory Medicine [Category] Fulltext, SARS, 임상, 진단,

[키워드] 95% CI adaptive adverse event analysed assigned Bayesian C-reactive protein (CRP Care colony stimulating factor Complete Concentration COVID-19 CRP Efficacy enrolled Evidence FIVE greater hospital hospitalised patient Inflammation inhibitor intensive care Interaction Intervention intravenous dose investigator ISRCTN Medical Research Council multi-arm multicentre Necrosis nine occurred Open-label outcome parallel-group participant Patient Phase 3 trials Pneumonia point estimate primary endpoint Primary outcome Probability randomised Randomly recruited reducing reduction in Registered screened Standard of care stratified treatment allocation Trial usual care usual care alone usual care group with COVID-19
[DOI] 10.1016/S2213-2600(21)00460-4 PMC 바로가기 [Article Type] Clinical Trial

Health-related quality of life of COVID-19 two and 12 months after intensive care unit admission

Research

Published on 2022-02-202022-10-28
Journal: Annals of Intensive Care [Category] COVID-19,

[키워드] acute respiratory distress syndrome Admission Algorithm alteration body mass index COVID-19 discharge discharged Dyspnea enrolled Exercise capacity Factor French Gender health-related quality of life help ICU ICU admission identify intensive care interquartile range male mechanical ventilation Medical Research Council mMRC Mortality Multiple linear regression normalized Patient patients proportion Pulmonary function tests Quality of life rehabilitation rehabilitation facility reported Result returned risk Six-minute walk test smoking subsequent supplementary material Symptom transferred were assessed
[DOI] 10.1186/s13613-022-00991-0 PMC 바로가기 [Article Type] Research

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Covid-19 (회복)로 병원에 입원 한 환자의 Casirivimab 및 Imdevimab : 무작위, 통제, 오픈 라벨, 플랫폼 시험

Randomized Controlled Trial

Published on 2022-02-122022-08-13
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료제,

[키워드] (Medical Research Council 1:1 28-day mortality 95% CI Administered Adverse reaction Adverse reactions All participants all randomly assigned patients all-cause mortality Analysis antibody assigned baseline baseline antibody status bleeding Cardiac arrhythmia Casirivimab cause-specific mortality clinically suspected Combination death detectable died dose Efficacy Efficacy and safety eligible Eligible participants enrolled evaluate finding funding hospital host cells humoral immune response Imdevimab Innovation Intention intention to treat intravenous infusion investigator investigators ISRCTN laboratory-confirmed SARS-CoV-2 infection Local major bleeding events Medical Research Council monoclonal antibody monoclonal antibody combination Mortality mounted non-competing monoclonal antibodies non-competing monoclonal antibody Open-label outcome p value participant Patient Platform trial Primary outcome randomisation randomised randomised, controlled, open-label platform trial Randomly randomly assigned patient rate ratio Receptor binding domain recovery reduced Registered reported Safety SARS-COV-2 infection SARS-CoV-2 spike glycoprotein SARS-CoV-2 vaccine Serious adverse reactions seronegative seronegative patient seronegative patients seropositive seropositive and seronegative patients Seven significantly single intravenous infusion spike glycoprotein Standard of care the SARS-CoV-2 thrombosis Treatment Trial UK hospital usual care usual care alone Viral viral entry with COVID-19
[DOI] 10.1016/S0140-6736(22)00163-5 PMC 바로가기 [Article Type] Randomized Controlled Trial

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients

Ad26.COV2.S 백신 수용자에서 동종 대 이종 부스트의 차등 면역원성

Article

Published on 2022-02-112022-09-11
Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Ad26 Ad26.COV2.S Ad26.COV2.S vaccine Adenovirus Adenovirus Vector Antiviral antiviral immunity BNT162b2 boost breadth cellular immune responses cellular immunity ChAdOx1 ChAdOx1 nCoV-19 college coronavirus disease Coronavirus disease 2019 COV2.S COVID-19 dose ENhance feature Heterologous heterologous immunity heterologous vaccine homologous homologous or heterologous humoral immune responses immunological immunological parameter individual individuals knowledge lack Medical Research Council Ministry of Health mRNA of BNT162b2 offered protection pump quantity recipient second dose Singapore single dose small sample size SMD specific antibodies spike-specific antibodies Spike-specific antibody Support supported T cell T cells Trustee utilization vaccination Vaccine Vaccines
[DOI] 10.1016/j.medj.2021.12.004 PMC 바로가기 [Article Type] Article

Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals

SARS-CoV-2에 대한 타액 IgG는 혈청 전환을 나타내며 mRNA 백신 접종 면역 저하된 개인의 혈청 중화와 상관 관계가 있습니다

Article

Published on 2022-02-112022-09-12
Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] acute respiratory syndrome ALF Allogeneic Analysis Anti-SARS-CoV-2 S antibody Antigen AUC Cancer CAR-T caused center CLL CLL patient comparable coronavirus correlated Council COVID-19 disease dose Elecsy entire cohort foundation group healthy control HIV Human immunodeficiency virus IgG IgG response IgG titer immunocompromised individual immunodeficiency Immunoglobulin immunosuppressants indicate individual Infection Innovation Knut leukemia Medical Research Council mRNA BNT162b2 mRNA BNT162b2 vaccine multiplex neutralizing capacity parameter participated Patient PID Positive predictive value PPV predictive power Primary Immunodeficiency primary site Prospective clinical trial reactivity receiver operating characteristic receptor Region response responses revaccination Saliva salivary SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 spike antigen Seroconversion serum Serum Neutralization solid organ transplantation SOT spike IgG Stem cell transplantation Stockholm County susceptible Swedish T cell therapy transplantation vaccination vaccine response Vaccine-induced immunity were measured
[DOI] 10.1016/j.medj.2022.01.001 PMC 바로가기 [Article Type] Article

Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett’s oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot

내시경 Barrett의 식도 감시를 우선시하기 위한 Cytosponge 바이오마커 패널 사용: 단면 연구에 이어 실제 전향적인 파일럿

Multicenter Study

Published on 2022-02-012022-09-10
Journal: The Lancet. Oncology [Category] COVID19(2023년), MERS, SARS, 바이오마커, 임상,

[키워드] age alternative Analysis atypia Barrett's oesophagus BEST2 BEST3 Biomarker Biomarkers Biopsy diagnosis Cancer Cancer Research UK cellular clinical clinical factor clinical factors Clinical practice Clinical research clinical risk clinical risk factor Clinical risk factors clinical trials Cohort conducted COVID-19 COVID-19 pandemic cross-sectional cross-sectional study Decision tree defined Demographic variables determined by Diagnosis dysplasia effective Endoscopic biopsy endoscopy evaluate evaluated feasibility finding FIVE funding gold gold standard group groups high risk identify Intervention intestinal intestinal metaplasia laboratory biomarker laboratory biomarkers lead Medical Research Council moderate multicentre network oesophagus overexpression p53 participant Pathways Patient patients patients older Positive predictive value Prague Predictive value Prevalence primary endpoint progression prospective cohort reduction in repeated retrospective risk Sex Surveillance TFF3 the primary endpoint tongue validation cohort
[DOI] 10.1016/S1470-2045(21)00667-7 PMC 바로가기 [Article Type] Multicenter Study